To address malaria outbreaks in Africa, two approved malaria vaccines have been deployed in eight countries, with measurable success.
As 2024 progresses, additional African countries will launch malaria vaccination programs.
Additionally, passive immunization products, which have been tested for years, are now conducting late-stage clinical trials.
These experimental monoclonal antibody therapies offer significant value in protecting children, pregnant women, and immunocompromised individuals from contracting malaria.
Read More
